Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Treatment options and their rollout for patients with metastatic urothelial carcinoma

Joaquim Bellmunt • 22 Oct 2023
ESMO 2023
Urothelial Carcinoma Antibodies Avelumab Cisplatin Enfortumab vedotin Gemcitabine Nivolumab Pembrolizumab
EV-302

Joaquim Bellmunt, MD, PhD, Harvard Medical School, Boston, MA, discusses the treatment options currently available to patients with metastatic urothelial cancer, delving into the associated challenges of distributing these drugs to a wider patient pool. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Joaquim Bellmunt

1:44
The impact of mutational clonality on patient response to immunotherapies in UC
Joaquim Bellmunt • 22 Oct 2023
1:08
Key takeaways from the renal and prostate cancer sessions at ESMO 2023
Joaquim Bellmunt • 22 Oct 2023
3:38
Breakthroughs in urothelial cancer treatment at ESMO 2023
Joaquim Bellmunt • 22 Oct 2023
0:59
Updates in kidney cancer at ESMO 2022
Joaquim Bellmunt • 12 Sep 2022

Related Videos

0:57
PROs in advanced cisplatin-ineligible UC: first-line EV ± pembrolizumab
Jonathan Rosenberg • 7 Apr 2024
1:05
HRQoL in patients with previously treated advanced urothelial carcinoma from EV-301: EV vs chemo
Jonathan Rosenberg • 7 Apr 2024
7:29
Neoadjuvant and adjuvant strategies in localized MIBC: current approaches and future directions
Daniele Raggi • 8 Dec 2023
9:49
Managing toxicities in advanced urothelial cancers: insights on EV and erdafitinib
Rob Jones • 6 Dec 2023
The content of VJOncology is intended for healthcare professionals